(RTTNews) – Biotechnology company Novavax, Inc. (NVAX) announced Monday that it reached a prior agreement with the Canadian government to deliver up to 76 million doses of Novavax’s COVID-19 vaccine.
Novavax and Canada plan to finalize an early procurement agreement whereo Novavax will supply doses of NVX-CoV2373 to Canada from the 2021 quarter. This procurement agreement will be subject to Health Canada’s approval of the Novavax vaccine.
NVX-CoV2373 is recently undergoing several Phase 2 clinical trials. Phase 2 of the Phase 1/2 clinical trial to evaluate the protection and immunogenicity of NVX-CoV2373 began in August in the United States and Australia.
Phases 1/2 expand the age organization of Phase 1 by incorporating adults over 60 to 84 years of age as approximately 50% of the study population. Secondary goals come with an initial assessment of effectiveness. In addition, a Phase 2b clinical trial was initiated to evaluate efficacy in the South. Africa in August.
NVX-CoV2373 was created using Novavax recombinant nanoparticle generation to generate an antigen derived from the complex protein (S) of coronavirus and comprises Novavax’s patented saponin-based Matrix-M adjuvant for immune reaction and stimulate maximum levels of neutralizing antibodies.